Derivatives of gylcero-manno-heptose adp for use in modulating immune response

A compound represented by formula (I):

• and/or a stereoisomer, tautomer, stable isotope, prodrug or pharmaceutically acceptable salt thereof, wherein:
• A1 and A2 are independently selected from O, S and —C(R8R9)—, wherein
• R8 and R9 are independently selected from H, D, —OH, N3, —CN, halogen and an optional substituted group selected C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkanoyloxy, C1-C4 alkenyloxy and aralkyloxy, wherein the optional substituents are 1-3 substituents independently selected from D, halogen, —OH, ═O, C1-C4 alkyl and C1-C4 alkoxy;
• at least one of A1 or A2 is —C(R8R9);
• wherein R8 or R9 in A1 can cyclize with R8 or R9 in A2 to form C3-C6 cycloalkyl and heterocyclyl containing 3 to 9 ring members and having 1-3 heteroatoms selected from N, O and S as ring members, each optionally substituted by 1-3 substituents independently selected from D, halogen, —OH, ═O, C1-C4 alkyl and C1-C4 alkoxy;
• L1 and L2 are independently selected from O, CH2, CHF and CF2;
• L3 is O, S or CH2;
• Z1 and Z2 are independently selected from O and S;
• W1 is —C(R10R11)—, wherein
• R10 and R11 are independently selected from H, D, —OH, halogen, and optionally substituted groups selected from C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4-haloalkoxy, C1-C4 alkenyloxy, aralkyloxy, 1-6 membered oligopeptidyl linked via C-terminal C(O)O— and R12CO2—, wherein
• R12 is selected from C1-C20 alkyl, C1-C20 alkenyl, C1-C20 alkoxy, C1-C20 alkenyloxy, C1-C20 alkylamino, C3-C6 cycloalkyl, heterocyclyl containing 4 to 6 ring members and having 1-3 heteroatoms selected from N, O and S as ring members, C6-C10 aryl, and heteroaryl containing 5 to 10 ring atoms and having 1-3 heteroatoms selected from N, O and S as ring members and 1-6 membered oligopeptidyl linked via N-terminal N;
• wherein the optional substituents for R10 and R11 are 1-3 substituents independently selected from D, halogen, —OH, ═O, C1-C4 alkyl and C1-C4 alkoxy;
• wherein when W1 is —C(R10R11)— and R10 is F, and the others are defined as above, W2 is H or C1-C3 alkyl optionally substituted with 1-3 substituents independently selected from D, halogen, —OH, ═O, C1-C3 alkoxyl, C1-C3 haloalkyl, C1-C3 haloalkoxyl, C1-C3 alkenyloxyl and R12CO2—, wherein R12 is C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C3-C6 cycloalkyl, cycloheteroalkyl containing 3 to 6 ring members and having 1-3 heteroatoms selected from N, O and S as ring members, C6-C10 aryl, and heteroaryl containing 5 to 10 ring atoms and having 1-3 heteroatoms selected from N, O and S as ring members;
• W2 is R13-Q1-W3—, wherein
• Q1 is selected from —O— or —NH—,
• W3 is selected from a bond or C1-C3 alkylene groups optionally substituted with 1-3 substituents independently selected from halogen, —OH, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C3 alkenyloxy,
• R13 is 1-6 membered oligopeptidyl linked via C-terminal carbonyl group or
• R14Q2C(O)—, wherein
• Q2 is a bond, —O— or —NH—,
• R14 is 1-6 membered oligopeptidyl linked via N-terminal N or an optionally substituted group selected from C5-C20 alkyl, C5-C20 alkylenyl and R15-Q3-Q4-Q5-, wherein
• Q3,Q4 and Q5 are independently selected from a bond, aryl, heteroaryl containing 5 to 6 ring atoms, C3-C6 cycloalkyl and heterocyclyl containing 4 to 6 ring members and having 1-3 heteroatoms selected from N, O and S as ring members, and at least one of Q3, Q4 and Q5 is not a bond,
• R15 is an optionally substituted group selected from C1-C18 alky and C1-C18 alkoxy;
• wherein the optional substituents for R14 and R15 are 1-3 substituents independently selected from halogen, —OH, —CO2H, C1-C4 alkyloxycarbony, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy C3-C6 cycloalkyl and C3-C6 cycloalkyloxy;
• R1 is aryl or heteroaryl containing 5 to 10 ring atoms and having 1-4 heteroatoms selected from N, O and S as ring members, wherein R1 is optionally substituted with 1-3 substituents selected from D, halogen, —OH, ═O, CN, NH2 and an optionally substituted group selected from C1-C4 alkyl, C1-C4 alkoxy, (R16R17)N— and (R16R17)NCO—, wherein
• R16 and R17 are independently selected from H and an optionally substituted group selected from C1-C4 alkyl, C3-C6 cycloalkyl, heterocyclyl containing 4 to 6 ring members and having 1-3 heteroatoms selected from N, O and S as ring members, aryl, arylalkyl, heteroaryl containing 5 to 10 ring atoms and having 1-3 heteroatoms selected from N, O and S as ring members;
• and heteroarylalkyl containing 5 to 10 ring atoms and having 1-3 heteroatoms selected from N, O and S as ring members;
• wherein the optional substituents are 1-3 substituents independently selected from from D, halogen, —OH, ═O, CN, NH2 and an C1-C4 alkyl, C1-C4 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy and C3-C6 cycloalkyl;
• R2, R3 and R4 are independently selected from H, D, halogen, C1-C4 alkyl and C1-C4 haloalkyl;
• R5, R6 and R7 are independently selected from H, —OH, halogen, and R12CO2—, and at least two of R5, R6 and R7 are OH or R12CO2—, wherein R12 is selected from C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkenyloxy, C1-C4 alkylamino, C3-C6 cycloalkyl, heterocyclyl containing 4 to 6 ring members and having 1-3 heteroatoms selected from N, O and S as ring members, C6-C10 aryl, and heteroaryl containing 5 to 10 ring atoms and having 1-3 heteroatoms selected from N, O and S as ring members;
• wherein any two of the adjacent groups of R5, R6 and R7 can cyclize to form heterocyclyl containing 5 to 9 ring members and having 1-3 heteroatoms selected from N, O and S as ring members, each optionally substituted by 1-3 substituents independently selected from D, halogen, —OH, ═O, C1-C4 alkyl and C1-C4 alkoxy.